Bavarian Nordic A/S  announced today that the Public Health Agency of Canada (PHAC) has ordered IMVAMUNE® smallpox vaccine to the national stockpile at a total value of USD 31.2 million.


Deliveries of the vaccines are expected to occur from the first quarter 2022 with anticipated completion in 2023. Hence this order, which is made under an existing contract with PHAC, will have no impact on the Company’s financial guidance for 2021.

Paul Chaplin, President & Chief Executive Officer of Bavarian Nordic, said: “We are very pleased to continue our collaboration with the Canadian government in their efforts to secure protection for its citizens. This collaboration dates back to 2008 when we started deliveries to the Canadian Department of National Defence and was since broadened to include the Public Health Agency of Canada, who also recognized the need for establishing a smallpox vaccine stockpile for the general population.”

Got Smallpox?

IMVAMUNE smallpox vaccine approved for monkeypox and related orthopoxvirus in Canada

Investigational smallpox vaccine, IMVAMUNE, has successful Phase 3 clinical trial

Canada orders 65,700 doses of IMVAMUNE smallpox vaccine